H1 2026 M&A Analysis: what this year’s deals tell us about the future of women’s health

By Anna O'Sullivan (Founder, FutureFemHealth) and Stephanie Silverman, CFA (Founder, Solstice)

Hello and welcome to a special edition of FutureFemHealth. Today we're turning our attention from who is funding women's health to who is buying it - and what those transactions reveal about where the sector is heading.

This piece is co-written by Anna O'Sullivan and Stephanie Silverman, CFA pairing FutureFemHealth's deal tracking and analysis with Solstice's capital markets analysis of the strategic and financial trends shaping women's health M&A.

Big capital showed up for women’s health in H1 2026. The question worth asking is what it bought.

The dollars were real: an $18 billion take-private, an $11.75 billion pharma deal and a long tail of more than 30 acquisitions that never printed a price but span fertility, menopause, diagnostics, software, pharmacy and mental health.

Across all of it the same pattern holds. Across the transactions, buyers consistently targeted businesses with established capabilities, recurring revenue models and strategic assets that could strengthen broader healthcare platforms.

One thing changed that matters more than any single deal: the buyer universe expanded.

Hologic went private to two of the largest PE firms and two sovereign wealth funds. Organon, one of the largest women’s health platforms in the world, changed hands to a non-U.S. pharma with the scale and appetite to keep acquiring. WPS, a health insurer, bought a clinical platform outright and called it the first step in a build.

A year ago, the women’s health exit ran one narrow path: build, scale and sell to a U.S. strategic. After H1 2026, there are more bidders at the table, private equity, sovereign wealth, global pharma and now payers, and a wider range of outcomes. That widens the options for founders and raises the bar at the same time, because these buyers reward durability and recurring revenue.

Below: FutureFemHealth Pro members can access the full H1 2026 deal tracker, the segment-by-segment breakdown and what each shift means for founders, investors and acquirers.